The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...
In patients with type 2 diabetes (T2D) with and without major adverse cardiovascular events (MACE), those who initiated dipeptidyl-peptidase-4 inhibitors (DPP-4i) as an add-on treatment to metformin ...
Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...
SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results